Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2010-12-20 Board/Management Inform…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Appointment of Alternate Director 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 21 December 2010 regarding the appointment of an alternate director, Ms Susanne Clay, for Professor Robert Elliott during his absence. The content is brief and focuses solely on a board/management change. There is no financial data, report, or regulatory filing referenced. This fits the category of Board/Management Information (MANG). The document length is very short (357 characters), consistent with a simple announcement rather than a detailed report.
2010-12-20 English
LCT Approved to Further Expand DIABECELL NZ Trial 2 pages ?Kb
Capital/Financing Update Classification · 90% confidence The document is a company announcement from Living Cell Technologies Limited regarding the approval to expand a clinical trial for their product DIABECELL. It discusses the addition of patients to a Phase II trial, dosage details, and clinical progress. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on clinical trial updates and regulatory approval for trial expansion, which is typical of a Capital/Financing Update or a general company announcement related to business progress. It is not an Annual Report, Earnings Release, or any detailed financial report. Given the nature of the announcement about trial expansion and regulatory approval, the most fitting classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the trial expansion, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2010-12-19 English
LCT`s DiabeCell Registered for Sale and Use in Russia 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited about the registration and commercialisation of their diabetes treatment product DIABECELL in Russia. It provides detailed information about the product, clinical trials, and the company's business strategy. There are no financial statements, quarterly or annual results, or regulatory filings such as certifications or voting results. The content is primarily a business update and product commercialization announcement rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general company announcement about a product milestone, which aligns best with the category of Regulatory Filings (RNS) as a fallback for miscellaneous company announcements that do not fit other specific categories.
2010-12-09 English
Final Director`s Interest Notice - Simon O`Loughlin 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and interests of a director who has ceased to be a director, including shares and options held. The content focuses on personal share transactions and holdings by a company director. There is no financial performance data, earnings information, or report publication. The document fits the definition of 'Director's Dealing' which reports personal share transactions by company directors and executives (insider trades). The document length is short and specific to director interests, confirming it is not a full report or announcement of a report.
2010-11-22 English
Final Director`s Interest Notice - David McAuliffe 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options held by related parties, and the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director, which fits the definition of Director's Dealing filings. The document length is short and focused solely on director interests, with no financial results or other report content. Therefore, the appropriate classification is Director's Dealing (DIRS).
2010-11-22 English
Final Director`s Interest Notice - David Brookes 3 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the securities holdings and options of a director who has ceased to be a director, including dates and share classes. This is a report of personal share transactions or holdings by a company director, which fits the definition of Director's Dealing filings. The document length is short and focused solely on director interests, with no financial statements or other report content. Therefore, it is classified as a Director's Dealing (DIRS) filing.
2010-11-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.